Telix's FDA-Approved Brain Cancer Imaging Drug Now Administered to US Patients

Telix Pharmaceuticals announced that Pixclara® (floretyrosine F 18), its FDA-approved PET imaging drug for glioma, has been administered to the first patients in the U.S. This marks the commercial availability of Pixclara, which helps differentiate recurrent brain cancer from treatment-related changes in adult and pediatric patients. The drug's rollout provides a new diagnostic tool for a serious condition.